VivoSeq
Other

Injury

258

Pipeline Programs↗

59

Active Trials↗

98

Companies Involved↗

Injury is a highly competitive landscape with 258 programs across 98 companies. The most active players are Cascade Pharmaceuticals, Inc, Vincentage Pharma Co., Ltd, Sclnow Biotechnology Co., Ltd.. 78 therapies are approved with 40 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

85/100

Pipeline Velocity

46/100

Mech. Concentration

7/100

Completion Rate

73/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cascade Pharmaceuticals, Inc

1 program

Phase 1V

Vincentage Pharma Co., Ltd

1 program

Phase 1S

Sclnow Biotechnology Co., Ltd.

1 program

Phase 1S

Shanghai Vinnerna Biosciences Co., Ltd.

1 program

Phase 1COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 1T

Taiwan Bio Therapeutics Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical49

Adenosine

Astellas

Statin

Bristol-Myers Squibb

Ropivacaine

Fresenius Kabi Oncology Ltd.

Prasugrel

Cosette Pharmaceuticals, Inc.

Immune Checkpoint Inhibitors

Peking Union Medical College Hospital

Phase 121

Psilocybin

COMPASS Pathways

Desflurane

Baxter Healthcare Corporation

Antioxidant Therapy

University of Chile

Acetylcholine

Bausch Health Americas, Inc.

Phenylephrine

Exela Pharma Sciences, LLC.

Phase 270

Epoetin Beta

Roche

Melatonin

Neurim Pharmaceuticals Ltd.

Ulinastatin

Techpool Bio-Pharma Co., Ltd.

Baricitinib

Eli Lilly

Glutamine

Sanofi

Phase 340

Dabigatran

Boehringer Ingelheim

Ketamine Hydrochloride

Boehringer Ingelheim

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Etoricoxib

Novartis

Dexketoprofen

Pamukkale University

Approved78

Vericiguat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Carboplatin

Avyxa

Oxytocin

Retrophin

Cefazolin

Baxter Healthcare Corporation

Hydromorphone

Rhodes Pharmaceuticals, L.P.

Analysis

Modality Breakdown

95%

Small molecule

287 of 303 classified programs — the dominant modality here.

5%ALL OTHERSCell therapy83%Monoclonal antibody3<1%Protein / enzyme3<1%Peptide2<1%

Small molecule leads; the ring shows all 303 classified programs, each share of the total. Modality classified for 100% of 325 pipeline programs.

Analysis

Trial Status

260

clinical trials

Completed100 · 38%
Unknown status57 · 22%
Recruiting33 · 13%
Terminated23 · 9%
Not yet recruiting20 · 8%
Withdrawn13 · 5%
Other14 · 5%

Clinical Trials

Trial Activity

260 trials

Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury
Recruiting·HHerzog Hospital·Phase 3·NCT06394284·60 enrolled
SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery
Recruiting·VVanderbilt University Medical Center·Phase 4·NCT05812755·170 enrolled
4-aminopyridine Treatment for Nerve Injury
Recruiting·—·Phase 2/3·NCT03701581·70 enrolled
Efficacy and Safety of Local Glucocorticoids for the Treatment of Acute Radiation-Induced Intestinal Injury
Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT06410443·60 enrolled
Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)
Recruiting·HHamilton Health Sciences Corporation·Phase 1·NCT06203977·200 enrolled
Antibiotic Use in Facial Fracture Post Injury
Recruiting·MMethodist Health System·N/A·NCT04925531·1,000 enrolled
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Recruiting·MMassachusetts General Hospital·Phase 2·NCT04485286·72 enrolled
Stellate Ganglion Morphine Infiltration on Myocardial I/R Injury
Recruiting·TThe Second Hospital of Anhui Medical University·N/A·NCT07023679·2,588 enrolled
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Recruiting·UUniversity of California, Davis·Phase 2·NCT02232191·75 enrolled
F573 for Injection for the Treatment of Liver Injury/Failure
Recruiting·BBeijing Continent Pharmaceutical Co, Ltd.·Phase 2·NCT05689645·97 enrolled
Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury
Recruiting·UUniversity of Manitoba·Phase 1·NCT01731444·24 enrolled
Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients
Recruiting·—·Phase 4·NCT05635877·2,000 enrolled
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
Recruiting·—·Phase 4·NCT07150624·96 enrolled
Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI
Recruiting·—·Phase 2·NCT06564909·76 enrolled
Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors
Recruiting·—·Phase 2·NCT05801133·41 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)